Abstract 12001: CHA2DS2-VASc Score Are More Predictive of Clinical Outcomes Compared With SYNTAX Score in Patients With Coronary Artery Disease
Purpose: To investigate the association among clinical outcomes, clinical variables (CHA2DS2-VASc score), and anatomical variables (SYNTAX score) in patients undergoing percutaneous coronary intervention (PCI) with coronary artery disease (CAD).
Methods: A cohort of 1701 patients (69.7±10.7 years old, 77% male) who underwent PCI for CAD was analyzed from ICAS (Ibaraki Cardiovascular Assessment Study) multi-center registry between April 2007 to April 2010. We divided patients into 3 groups according to tertile of SYNTAX score; Low SYNTAX (0-8: n=567), Mid SYNTAX (9-15: n=567), and High SYNTAX (≧16: n=567). And we also divide into 3 subgroups on the basis of CHA2DS2-VASc score (low: 0-2, mid: 3-5, high: 6-8 point). Clinical outcomes were defined as major adverse cardiovascular event (MACE) which included all cause death, myocardial infarction, stroke, or hospitalization for worsening heart failure.
Results: Mean follow up period was 440 days. Incidence of MACE was significantly increased according to increasing CHA2DS2-VASc score in high and low SYANTAX groups (figure). There was no relation between increasing SYNTAX score and MACE in each CHA2DS2-VASc subgroups. Receiver operating characteristics curve (ROC) showed area under the curve (AUC) was larger in CHA2DS2-VASc score than SYNTAX score for MACE (0.613 vs. 0.498). CHA2DS2-VASc score was an independent predictor of MACE after adjustment of multiple cofounders (per increase, OR: 1.30, 95% confidence interval: 1.17-1.43, p<0.001), but not SYNTAX score (per increase, OR: 0.99, 95% confidence interval: 0.98-1.01, p=0.56).
Conclusion: High CHA2DS2-VASc score provides worse clinical outcomes compared with SYNTAX score in patients with CAD in this registry.
Author Disclosures: D. Abe: None. A. Sato: None. T. Harunari: None. M. Misaki: None. Y. Kakefuda: None. T. Hoshi: None. K. Aonuma: None.
- © 2014 by American Heart Association, Inc.